PMA device
IPRO2 CGM System with Enlite Sensor
Medtronic Minimed · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Jun 17, 2016, newest Jun 17, 2016Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
15
Naming "IPRO2 CGM"
MAUDE reports
0
Brand "IPRO2 CGM", since 2015
PubMed studies
0
Mentioning "IPRO2 CGM"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P150029 · Decided Jun 17, 2016 · 312 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "IPRO2 CGM", any status and sponsor, newest update first.
East Tennessee State UniversityAcademic, hospital or other
NCT03067480 · 12 participants · Start Jun 6, 2017 · Primary completion Sep 30, 2019
Device: iPro2 Professional CGM · For: T2DM (Type 2 Diabetes Mellitus); Continuous Glucose Monitoring
Sites: Johnson City, Tennessee
Nordsjaellands HospitalAcademic, hospital or other
NCT05095259 · 60 participants (planned) · Start Dec 16, 2019 · Primary completion Dec 2023
Device: IPRO 2 Medtronic Minimed; Freestyle Libre 2 · For: Type1diabetes
Sites: Gentofte Municipality, Denmark; Hillerød, Denmark
Croatian Society for Endocrinology and DiabologyAcademic, hospital or other
NCT03487887 · 100 participants · Start Mar 19, 2018 · Primary completion Aug 25, 2021
Device: continuous glucose monitoring (CGM) iPro™2 Medtronic · For: Diabetes Mellitus, Type 2
Sites: Zagreb, Croatia
Pusan National University HospitalAcademic, hospital or other
NCT04369833 · 130 participants · Start May 11, 2020 · Primary completion Sep 30, 2020
Device: continuous glucose monitoring system · For: PreDiabetes; Glucose Metabolism Disorders; Diabetes Mellitus
Sites: Busan, South Korea
- The Efficacy of Guardian Connect to Modify Lifestyle in Patients With Type 2 Diabetes MellitusCompleted
Kangbuk Samsung HospitalAcademic, hospital or other
NCT05150041 · 60 participants · Start Apr 7, 2020 · Primary completion Dec 7, 2021
Device: Guardian connect; iPro2 · For: Diabetes Mellitus, Type 2
Sites: Seoul, South Korea
Becton, Dickinson and CompanyPublic (BDX)
NCT01645696 · 30 participants · Start Jun 2012 · Primary completion Sep 2012
Device: BD CGM with Outer Layer; BD CGM without Outer Layer and 1 more · For: Diabetes
Sites: Toronto, Canada
Children's Hospital Los AngelesAcademic, hospital or other
NCT02813421 · 11 participants · Start Mar 2016 · Primary completion May 1, 2017
Device: CGM Informed · For: Type 1 Diabetes Mellitus
Sites: Los Angeles, California
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du DiabèteAcademic, hospital or other
NCT02521675 · 50 participants · Start Jan 2016 · Primary completion Mar 2020
Device: Holter Glycemic Ipro2, Medtronic · For: Diabetes Mellitus, Type I; Adjustment of Basal Insulin Flow Rate During Physical Activity; Adjustment of Prandial Insulin in Case of Physical Activity
Sites: Angers, France; Avignon, France; Besançon, France · 17 sites in all
University Hospital, Gentofte, CopenhagenAcademic, hospital or other
NCT03150030 · 42 participants · Start Feb 1, 2017 · Primary completion Jan 6, 2020
Device: Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA); Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA) · For: Diabetes Mellitus, Type 2; Arrhythmia, Cardiac
Sites: Hellerup, Denmark
Associacao Protectora dos Diabeticos de PortugalAcademic, hospital or other
NCT04141111 · 102 participants · Start Mar 22, 2015 · Primary completion Jan 24, 2017
Device: Continuous Glucose Monitoring (CGM) · For: Diabetes Mellitus, Type 2
Sites: Lisbon, Portugal
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "IPRO2 CGM", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0670-2018 · Started Oct 10, 2017
Reason given: Due to a time conversion error, data uploaded from the iPro(TM)2 recorder to the CareLink iPro software using the new CareLink iPro Uploader feature may result in incorrect reports. This pertains only to reports generated between September 23, 2017 and September 27, 2017 that used the new CareLink iPro Uploader...
Cause as FDA categorized it: Software Manufacturing/Software Deployment · Device type: Automated Insulin Dosing , Threshold Suspend (OZO)
Published research
The most relevant PubMed records for "IPRO2 CGM"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.